FDA clears Lilly’s Retevmo for RET-positive lung, thyroid cancersEli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting Share XFDA clears Lilly’s Retevmo for RET-positive lung, thyroid cancershttps://pharmaphorum.com/news/fda-clears-lillys-retevmo-for-ret-positive-lung-thyroid-cancers/
Lilly keeps ahead of Blueprint with swift FDA review for selpercatinibEli Lilly says it is eyeing an FDA verdict for RET-positive tumour treatment selpercatinib in the third quarter Share XLilly keeps ahead of Blueprint with swift FDA review for selpercatinibhttps://pharmaphorum.com/news/lilly-keeps-ahead-of-blueprint-with-swift-fda-review-for-selpercatinib/
Relief for Lilly as drug from $8bn Loxo deal clears pivotal trialEli Lilly’s $8 billion acquisition of Loxo Oncology looks like it could pay off, with new data for Share XRelief for Lilly as drug from $8bn Loxo deal clears pivotal trialhttps://pharmaphorum.com/news/relief-for-lilly-as-drug-from-8bn-loxo-deal-clears-pivotal-trial/
